OncoMatch/Clinical Trials/NCT05296304
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Is NCT05296304 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Bexarotene for cutaneous t-cell lymphoma.
Treatment: Bexarotene — The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin. The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage IB OR HIGHER (ISCL/EORTC)
Stage IB or higher MF per ISCL/EORTC criteria; concurrent diagnosis of Sézary syndrome permissible.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: oral retinoid therapy
Cannot have received: total skin electron beam therapy
Exception: prior focal skin-directed rt acceptable
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) · New York, New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) · Rockville Centre, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify